Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.7% – Still a Buy?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) rose 4.7% during mid-day trading on Monday. The company traded as high as $28.15 and last traded at $28.3770. 177,749 shares were traded during mid-day trading, a decline of 73% from the average session volume of 664,715 shares. The stock had previously closed at $27.11.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Tuesday, September 22nd. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. Finally, Citigroup initiated coverage on shares of Maze Therapeutics in a report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $63.40.

Maze Therapeutics Trading Down 3.8%

The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $1.48 billion, a P/E ratio of -10.58 and a beta of 2.16. The business has a 50 day moving average of $26.84 and a 200-day moving average of $27.08.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). Analysts anticipate that Maze Therapeutics, Inc. will post -2.70 EPS for the current fiscal year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares in the company, valued at approximately $182,252.07. This represents a 22.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $27.02, for a total value of $932,217.02. Following the completion of the sale, the chief executive officer directly owned 15,558 shares in the company, valued at approximately $420,377.16. This represents a 68.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 192,991 shares of company stock valued at $5,152,084. 5.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the 2nd quarter valued at about $48,000. Royal Bank of Canada increased its position in Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after buying an additional 1,383 shares during the last quarter. Quantbot Technologies LP acquired a new position in Maze Therapeutics during the second quarter worth approximately $80,000. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the fourth quarter worth approximately $145,000. Finally, Persistent Asset Partners Ltd bought a new stake in Maze Therapeutics in the second quarter valued at approximately $200,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.